Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Orgenesis Inc (ORGS)

Orgenesis Inc (ORGS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 6,239
  • Shares Outstanding, K 4,799
  • Annual Sales, $ 530 K
  • Annual Income, $ -55,360 K
  • EBIT $ -56 M
  • EBITDA $ -55 M
  • 60-Month Beta 1.31
  • Price/Sales 12.68
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.13
  • Most Recent Earnings $-1.93 on 11/13/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 157.70%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8700 +49.43%
on 12/18/24
1.4800 -12.16%
on 12/03/24
+0.2100 (+19.27%)
since 11/20/24
3-Month
0.8700 +49.43%
on 12/18/24
5.4400 -76.10%
on 09/27/24
-3.8740 (-74.87%)
since 09/20/24
52-Week
0.8700 +49.43%
on 12/18/24
10.7990 -87.96%
on 08/14/24
-3.2010 (-71.12%)
since 12/20/23

Most Recent Stories

More News
Orgenesis Provides Third Quarter 2024 Business Update

ORGS : 1.3000 (-7.14%)
Orgenesis Commences Trading on OTCQX® Best Market

ORGS : 1.3000 (-7.14%)
Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022

GERMANTOWN, Md., May 24, 2022 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...

ORGS : 1.3000 (-7.14%)
Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant

Focus is to Develop Cost-effective Production of Autologous Induced Pluripotent Stem Cells (iPSCs) using Microfluidic Technologies and Artificial...

ORGS : 1.3000 (-7.14%)
Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update

Orgenesis to host conference call today at 12:00 PM ET...

ORGS : 1.3000 (-7.14%)
Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid

Orgenesis achieves milestone in the placement of the Orgenesis Mobile Processing Units and Lab (OMPUL) for the development of cell and gene therapies at...

ORGS : 1.3000 (-7.14%)
Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

Center will expand Orgenesis’ Point of Care (POCare) Platform Capabilities in Maryland...

ORGS : 1.3000 (-7.14%)
Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year

Orgenesis to host conference call today at 8:30AM ET...

ORGS : 1.3000 (-7.14%)
Orgenesis Schedules Third Quarter 2021 Business Update Conference Call

GERMANTOWN, Md., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to...

ORGS : 1.3000 (-7.14%)
Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform

Goal to accelerate development, QC testing and manufacturing  of Orgenesis’ cell and gene therapy platform

ORGS : 1.3000 (-7.14%)

Business Summary

Orgenesis, Inc. is a biopharmaceutical company. It focused on developing its trans-differentiation technologies for diabetes. The company deals with the combination of cell-based therapy and regenerative medicine into clinical development. Its operating segment consists of Contract Development and Manufacturing...

See More

Key Turning Points

3rd Resistance Point 1.5333
2nd Resistance Point 1.4667
1st Resistance Point 1.3833
Last Price 1.3000
1st Support Level 1.2333
2nd Support Level 1.1667
3rd Support Level 1.0833

See More

52-Week High 10.7990
Fibonacci 61.8% 7.0061
Fibonacci 50% 5.8345
Fibonacci 38.2% 4.6629
Last Price 1.3000
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar